drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Biosimilar chimeric IgG1 anti–TNF-α monoclonal antibody. Binds soluble and transmembrane TNF-α, blocks TNFR1/TNFR2 signaling, induces apoptosis and immune clearance of TNF-expressing cells via ADCC/CDC, and suppresses NF-κB–mediated inflammation and associated cytokines.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous, Subcutaneous
drug_mechanism_of_action
Chimeric IgG1 anti-TNF-alpha monoclonal antibody (biosimilar infliximab) that binds soluble and transmembrane TNF-alpha, neutralizing it and blocking TNFR1/TNFR2 signaling; also mediates ADCC and CDC to deplete TNF-expressing cells, leading to suppression of NF-kB-driven inflammation and proinflammatory cytokines.
drug_name
CT-P13 (infliximab; Remsima SC)
nct_id_drug_ref
NCT05722353